TNFSF11 and postmenopausal osteoporosis: Denosumab, which is a RANKL (receptor activator of nuclear factor kappa-B ligand) inhibitor, and teriparatide (i.e., recombinant human parathyroid hormone (1–34)), are drugs that are expected to increase the BMD of women with postmenopausal osteoporosis more effectively than bisphosphonates (9, 10).